Slide 1: Q1 2022 Results
Q1 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 11, 2022
Slide 2: Executive summary, Financial overview, Guidance 2022, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 2
Slide 3: Highlights - FY 2022 started with record quarter
Highlights - FY 2022 started with record quarter Ongoing progress in strategy implementation • Successful acquisition: NewCo Pharma (PST) significantly strengthens market position in the area of compounding • Implementation of ESG-strategy underway Pharmaceutical Supply (PS): Operations • Significan
Slide 4: Excellent geographic coverage through strong nationwide network of partners and own compounding facilities
Excellent geographic coverage through strong nationwide network of partners and own compounding facilities • 7 GMP1 / blistering labs Hamburg • 2 warehouses Berlin (HQ) Osnabruck • Around 600 specialized partner Berlin pharmacies Cologne • Around 320,000 individualized preparations manufactured in 2
Slide 5: Another record quarter: Continuous quarterly increase of key figures
Another record quarter: Continuous quarterly increase of key figures Revenue €m EBITDA pre¹ €m 393 369 14.1 354 319 316 10.0 10.2 9.5 8.8 163 160 174 130 4.8 4.3 3.8 3.6 2.7 margin 2.5 2.2 3.0 2.8 2.8 2.7 2.3 1.6 1.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 2020 2021 2022
Slide 6: Q1 2022 – Strong earnings growth
Q1 2022 – Strong earnings growth Revenue €m EBITDA pre¹ €m 393 14.1 316 8.8 Q1 2021 Q1 2022 Q1 2021 Q1 2022 ¹ EBITDA without extraordinary expenses: adjusted for extraordinary expenses for stock options, M&A activities and amortization of the customer 6 base
Slide 7: Q1 2022 – Split by segments: Share of PST substantially increased
Q1 2022 – Split by segments: Share of PST substantially increased Revenue by segment EBITDA pre by segment 14% 48% 86% 52% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies 7
Slide 8: Ambitious ESG strategy 2025: 34 targets, 65 measures, 57 KPIs
Ambitious ESG strategy 2025: 34 targets, realized through 65 measures using 57 different KPIs Implementation process of IT-based ESG-platform 2023 and beyond Started • Sustainability reporting in full accordance with GRI1 for FY 2022 Membership in UN Global Compact extended • Achieve climate neutral
Slide 9: Executive summary, Financial overview, Guidance 2022, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 9
Slide 10: Q1 2022 – Record quarter driven by external growth
Q1 2022 – Record quarter driven by external growth In € million Q1 2022 Q1 2021 ∆% Revenue 393.0 315.9 24.4 • Strong revenue growth mainly driven by Gross profit 15.8 NewCo Pharma acquisition 26.2 65.7 gross margin in % 6.7 5.0 • Disproportionately increased gross profit EBITDA pre1 14.1 8.8 60.7 an
Slide 11: Q1 2022 – Strong organic and inorganic revenue growth
Q1 2022 – Strong organic and inorganic revenue growth Inorganic Q1 YoY Revenue in €m Q1 2021 Organic Q1 2022 (NewCo only) Pharmaceutical Supply 299.6 26.2 13.4 339.2 • Organic increase in PS mainly due to Patient-specific Therapies 16.1 0.7 36.8 53.6 synergy effects as a result of the acquisitions S
Slide 12: Q1 2022 – EBITDA pre driven by acquisition of NewCo Pharma
Q1 2022 – EBITDA pre driven by acquisition of NewCo Pharma Inorganic Q1 YoY EBITDA pre1 in €m Q1 2021 Organic Q1 2022 (NewCo only) Pharmaceutical Supply 7.0 0.4 0.9 8.4 • Slight organic increase in PS Patient-specific Therapies 2.2 0.0 4.7 6.9 • Successful integration of NewCo Pharma led to EBITDA p
Slide 13: Q1 2022 – Strong Group margin, mainly as a result of increased PST share
Q1 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply Therapies IFRS consolidation In € million Q1 2022 Q1 2021 Q1 2022 Q1 2021 Q1 2022 Q1 2021 Q1 2022 Q1 2021 Revenue1 339.2 299.6 53.6 16.1 0.1 0.1 393.0 315.9 del
Slide 14: Executive summary, Financial overview, Guidance 2022, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 14
Slide 15: Forecast FY 2022 confirmed
Forecast FY 2022 confirmed In € million 2022F¹ 2021 Growth % Group revenue 1,450 – 1,600 1,357.4 6.8 – 17.9 + External growth will be substantially driven by the acquisition of NewCo Pharma + Synergy effects as a result of the integration of the acquisitions of Cranach Pharma & Newco Pharma: EBITDA
Slide 16: Growth strategy - Clear plan for overall growth
Growth strategy - Clear plan for overall growth • Compounding capacities to triple as a result of • Compounding from partner pharmacies to be new labs in Berlin potentially integrated into Medios’ labs • Advance market penetration through innovative • Add further labs in case of geographical fit and
Slide 17: Executive summary, Financial overview, Guidance 2022, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 17
Slide 18: Key figures
Key figures in € thousand Q1 2022 Q1 2021 ∆ in % in € thousand Q1 2022 Q1 2021 ∆ in % Revenue 392,955 315,908 24.4 Earnings per share (in €) Pharmaceutical Supply 339,205 299,628 13.2 Undiluted 0.21 0.15 40.0 Patient-Specific Therapies 53,609 16,134 232.3 Diluted 0.21 0.14 50.0 Services 141 145 -2.8
Slide 19: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 19
Slide 20: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 21: Q1 2022 Results
Q1 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 11, 2022